BioMarin Pharmaceutical Inc. (BMRN) News
Follow BioMarin Pharmaceutical Inc. (BMRN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 48 public stories across 17 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
BioMarin Reports Third-Quarter Revenue of $1.02 Billion
Revenue rose 32% from $776.1 million a year earlier. Net loss widened to $122.8 million from $30.7 million, and diluted loss per share increased to $0.63 from $0.16.
EQUITY | Nov 03, 2026, 09:42 PM UTC
M
Analysts Lower BioMarin Price Targets After Q3 Earnings
Oppenheimer cut its target to $94 from $97, RBC to $60 from $62, and Wedbush to $89 from $94. All three firms maintained their existing ratings.
EQUITY | Nov 03, 2026, 07:03 PM UTC
M
BMRN Reports Fiscal Q3 Profit, Down 93.06% Year Over Year
Basic earnings per share were reported; the source gives no supported dollar amount.
EQUITY | Nov 03, 2026, 05:33 AM UTC
M
BioMarin falls after lowering annual forecast
BioMarin Pharmaceutical shares fell after the company lowered its annual forecast.
EARNINGS | Nov 02, 2026, 09:58 PM UTC
M
BioMarin Q3 non-GAAP diluted EPS rises 92% to $0.23
BioMarin Pharmaceutical reported third-quarter non-GAAP diluted EPS of $0.23, up 92%.
EARNINGS | Nov 02, 2026, 09:29 PM UTC
M
BioMarin Q3 Revenue Rises on Amicus Acquisition, Adjusted EPS Beats
EQUITY | Nov 02, 2026, 09:22 PM UTC
M
BioMarin sets FY revenue outlook at USD 3,800-3,900 million
EARNINGS | Nov 02, 2026, 09:13 PM UTC
M
BioMarin’s Q3 2026 Net Loss More Than Triples
EQUITY | Nov 02, 2026, 09:12 PM UTC
M
BioMarin Pharmaceutical Reports Third-Quarter Revenue of $1.02 Billion
EQUITY | Nov 02, 2026, 09:07 PM UTC
L
BioMarin posts Q3 adjusted EPS of $0.23 per share
EARNINGS | Nov 02, 2026, 09:07 PM UTC
L
BioMarin Pharmaceutical reports Q3 EPS of USD -0.63
EARNINGS | Nov 02, 2026, 09:06 PM UTC
M
BioMarin Reports Third-Quarter 2026 Financial and Operating Results
EQUITY | Nov 02, 2026, 09:06 PM UTC
M
BioMarin Q3 Adjusted EPS USD 0.23 vs. IBES Estimate USD 0.12
EARNINGS | Nov 02, 2026, 09:06 PM UTC
M
BioMarin reports Q3 net loss
EQUITY | Nov 02, 2026, 09:06 PM UTC
M
BioMarin Q3 EPS Is USD -0.63; Revenue $1,025 Million
BioMarin reported Q3 revenue of USD 1,025 million versus an IBES estimate of USD 1,026 million.
EQUITY | Nov 02, 2026, 09:04 PM UTC
M
BioMarin Reports 3Q Loss of $122.8M
EARNINGS | Nov 02, 2026, 09:03 PM UTC
M
Hanmi Pharmaceutical Signs Fabry Drug Licensing Deal With BioMarin Worth Up to $237.5 Million
Hanmi Pharmaceutical signed a licensing deal with BioMarin for a Fabry disease drug, worth up to USD 237.5 million.
MNA | Oct 29, 2026, 10:48 PM UTC
M
GC Biopharma Signs Fabry Drug Licensing Deal With BioMarin
The licensing deal is worth up to USD 237.5 million.
MNA | Oct 29, 2026, 10:45 PM UTC
M
BioMarin Licenses Fabry Disease Therapy From GC Biopharma and Hanmi Pharm
BioMarin entered an exclusive license for a Fabry disease therapy from GC Biopharma and Hanmi Pharm.
EQUITY | Oct 29, 2026, 12:50 PM UTC
M
BioMarin Signs Fabry Disease Treatment Development Deal
BioMarin signed an agreement with GC Biopharma and Hanmi to develop a treatment for Fabry disease.
EQUITY | Oct 29, 2026, 12:49 PM UTC
L
BioMarin halts studies for Voxzogo in Noonan syndrome
Shares of BioMarin Pharmaceutical NASDAQ:BMRN slipped in premarket trading on Tuesday after the company announced plans to discontinue the development of its dwarfism therapy Voxzogo for Noonan syndrome, a rare genetical
EQUITY | Sep 15, 2026, 01:11 PM UTC
L
BioMarin discontinues VOXZOGO development for Noonan syndrome in children
BioMarin announced it will discontinue development of VOXZOGO for children with Noonan syndrome.Key Highlights:Original SEC Filing: BIOMARIN PHARMACEUTICAL INC [ BMRN ] - 8-K - Sep. 15, 2026This is an AI-powered summary.
REGULATION | Sep 15, 2026, 12:33 PM UTC
L
BMRN: Portfolio expansion, Amicus deal, and VOXZOGO growth drive strong outlook and pipeline innovation
The conference highlighted robust portfolio expansion, including the Amicus acquisition, which adds two high-growth assets and is expected to drive significant revenue and EPS accretion. VOXZOGO continues strong global g
EARNINGS | Sep 10, 2026, 03:09 PM UTC
L
HC Wainwright maintains BioMarin’s $60.00 price target
EQUITY | Sep 10, 2026, 10:46 AM UTC
L
BMRN: Strong growth, pipeline expansion, and global market execution drive future momentum
Metabolic and skeletal franchises are driving robust growth, with VOXZOGO expanding globally and new pipeline assets advancing in hypochondroplasia, DMD, HPP, and FSGS. Strategic deals, a strong commercialization platfor
EQUITY | Sep 09, 2026, 09:02 PM UTC
L
BMRN: Robust growth, pipeline expansion, and global execution position the business for sustained success
Metabolic and skeletal franchises are driving strong revenue growth, with VOXZOGO and Amicus products expanding globally. R&D pipeline advances include promising hypochondroplasia data, new deals, and upcoming readouts f
EQUITY | Sep 09, 2026, 08:02 PM UTC
L
Ten healthcare stocks with A-rated valuations and strong revenue growth
Healthcare stocks remain a focal point for investors as pharmaceutical innovation, biotechnology advancements, and managed care expansion continue to drive growth across the sector.While many healthcare companies trade a
EQUITY | Sep 09, 2026, 03:01 PM UTC
M
BioMarin announces positive Phase 3 VOXZOGO results in NEJM
BioMarin said its Phase 3 VOXZOGO (vosoritide) study in hypochondroplasia has positive results, published as NEJM evidence.
EQUITY | Sep 09, 2026, 01:07 PM UTC
L
BioMarin EVP, Chief Legal Officer sells $1,163,748 in shares
BioMarin officer Davis George Eric, EVP and Chief Legal Officer, sold 17,557 common shares on 2026-09-02 for $1,163,748. Weighted average price was $66.284; executed prices ranged from $66.271 to $66.39.
EQUITY | Sep 03, 2026, 11:20 PM UTC
L
BMRN - BioMarin to Participate in Upcoming Investor Conferences
BMRN - BioMarin to Participate in Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 01:01 PM UTC
L
BioMarin management to present at September investor conferences
BioMarin Pharmaceutical management will present at upcoming investor conferences in September. An audio webcast of the presentations will be available live.
EQUITY | Sep 02, 2026, 01:01 PM UTC
L
Piper Sandler keeps BioMarin at Overweight, lifts price target
Piper Sandler maintains BioMarin Pharmaceutical at Overweight and raises its price target to $90.00 per share from $88.00.
EQUITY | Sep 01, 2026, 05:29 PM UTC
L
BioMarin completes acquisition of Alesta subsidiary
BioMarin completed the acquisition of Alesta, which became a wholly owned subsidiary after the August 31, 2026 closing.
MNA | Sep 01, 2026, 01:34 PM UTC
L
BioMarin closes Alesta Therapeutics acquisition
BioMarin (BMRN) announced the close of its acquisition of Alesta Therapeutics.
MNA | Sep 01, 2026, 01:05 PM UTC
L
BioMarin Pharmaceutical maintained at Buy by Jefferies
Jefferies maintained its Buy rating on BioMarin Pharmaceutical.
EQUITY | Aug 31, 2026, 05:43 PM UTC
L
ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged
ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged
EQUITY | Aug 31, 2026, 05:30 PM UTC
L
Crude oil gains over 2%; Dallas Fed index surges in August
The Dallas Fed's general business activity index for Texas manufacturing rose to 11.6 in August from 1.3 in July, its strongest reading since January 2025.
CENTRAL_BANK | Aug 31, 2026, 04:46 PM UTC
L
BioMarin price target raised to $60 by HC Wainwright
HC Wainwright & Co. raised its BioMarin Pharmaceutical price target to $60.00/share from $59.00.
EQUITY | Aug 31, 2026, 04:08 PM UTC
M
BioMarin announces global settlement with Ascendis over Yuviwel royalties
BioMarin says Ascendis will pay royalties to BioMarin on Yuviwel sales in the U.S., EU, Brazil and South Korea under a global settlement.
EQUITY | Aug 31, 2026, 06:00 AM UTC
L
BMO, Wedbush, Wolfe and RBC issue stock initiations
BMO, Wedbush, Wolfe, RBC and Cantor initiate coverage with ratings changes on AKTS, ALNY, ASND, BCAX, BMRN, CATX, PRME, AFL, AGMB, COR and MCK.
EQUITY | Aug 19, 2026, 11:09 AM UTC
L
BioMarin agrees to buy Alesta Therapeutics for ALE1 asset
BioMarin Pharmaceutical agreed to purchase Alesta Therapeutics, including the clinical-stage asset ALE1, for $275 million upfront plus up to $215 million in milestone payments and expects revised full-year 2026 guidance
EARNINGS | Aug 18, 2026, 05:37 PM UTC
H
BioMarin to Acquire Alesta Therapeutics for Hypophosphatasia Program
BioMarin (BMRN) announces an acquisition of Alesta Therapeutics to gain ALE1, described as a potential first oral therapy for hypophosphatasia, adding a clinical program to its pipeline.
MNA | Aug 18, 2026, 12:31 PM UTC
L
BioMarin Pharmaceutical Raises FY2026 Adj EPS Guidance from $4.85-$5.05 to $4.90-$5.10 vs $3.64 Est; Raises FY2026 Sales Guidance from $3.82
BioMarin Pharmaceutical (NASDAQ: BMRN ) raises FY2026 Adj EPS guidance from $4.85-$5.05 to $4.90-$5.10 vs $3.64 analyst estimate. Raises FY2026 sales outlook from $3.825 billion-$3.925 billion to $3.875 billion-$3.925 bi
EARNINGS | Aug 06, 2026, 08:14 PM UTC
L
BMRN BMRN - BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET - C
BMRN BMRN - BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET
EARNINGS | Jul 30, 2026, 01:01 PM UTC
L
BMRN Biomarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified
BMRN Biomarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome ReNU syndrome was discovered in 2024 and there are no Medicines ap
EQUITY | Jul 27, 2026, 01:06 PM UTC
L
BioMarin Says FDA Accepts Filing for Voxzogo's Full Approval in Children With Achondroplasia
() -- BioMarin Pharmaceutical (BMRN) said Monday that the US Food and Drug Administration has accepted its supplemental new drug application seeking full approval of Voxzogo to treat children with achondroplasia. The reg
REGULATION | Jul 13, 2026, 01:37 PM UTC
L
BioMarin announces FDA accepts sNDA for full approval of Voxzogo
BioMarin Pharmaceutical...
REGULATION | Jul 13, 2026, 01:08 PM UTC
H
BioMarin price target lowered to $62 from $66 at RBC Capital
RBC Capital analyst Luca Issi lowered the firm's price target on BioMarin to $62 from $66 and keeps a Sector Perform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech
RATES | Jul 07, 2026, 11:28 AM UTC